Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISHL12 2022 | The importance of assessing cardiac risk in patients undergoing treatment for HL

Jenica Upshaw • 19 Sep 2022
ISHL12 2022
Hodgkin Lymphoma Lymphoma

Jenica Upshaw, MD, Tufts University, Boston, MA, shares some insights into the importance of assessing cardiac risk factors in patients with Hodgkin lymphoma (HL) undergoing treatment, highlighting the importance of evaluating symptoms and conducting post-treatment echocardiograms. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jenica Upshaw

3:07
The effect of heart failure on the management and outcomes of older patients with Hodgkin lymphoma
Jenica Upshaw • 19 Oct 2022
1:10
The importance of cardio-oncology in the treatment of patients with hematological malignancies
Jenica Upshaw • 19 Oct 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals